Next |
home / stock / ipha / ipha message board
Subject | By | Source | When |
---|---|---|---|
MomentumIts trading | lakoob2 | investorshub | 07/07/2023 2:27:48 PM |
Do we have a winner?Turn around time? | TheFinalCD | investorshub | 07/07/2023 5:16:31 AM |
$IPHA Good news recently, we should start to see this one move | tw0122 | investorshub | 07/05/2023 12:18:57 PM |
$IPHA short squeeze | crudeoil24 | investorshub | 07/05/2023 7:50:06 AM |
$IPHA where is the squeeze? | makinezmoney | investorshub | 07/03/2023 7:30:10 PM |
The now up | makinezmoney | investorshub | 07/01/2023 10:58:28 PM |
$IPHA Price gaining last trade up | crudeoil24 | investorshub | 06/28/2023 1:35:50 PM |
$IPHA Time for this to show some returns | makinezmoney | investorshub | 06/25/2023 1:58:14 PM |
short squeeze signal | makinezmoney | investorshub | 06/23/2023 7:05:12 PM |
what do you make of this data? | Beamer00 | investorshub | 06/23/2023 6:10:34 PM |
$IPHA bears and bulls | makinezmoney | investorshub | 06/19/2023 10:01:55 PM |
$IPHA Looks pretty positive | adamski | investorshub | 06/19/2023 4:50:11 AM |
The now | makinezmoney | investorshub | 06/18/2023 4:04:54 PM |
got some short data | crudeoil24 | investorshub | 06/17/2023 6:15:26 PM |
$IPHA Price trading | TheFinalCD | investorshub | 06/15/2023 3:52:10 PM |
$IPHA short squeeze | makinezmoney | investorshub | 06/14/2023 1:37:18 AM |
$IPHA Price trading up | makinezmoney | investorshub | 06/13/2023 11:35:22 AM |
znewcar1: $IPHA 39% v2,5M c2.65 f80,212M H2.86 ML1.9 YL1.96 | znewcar1 | investorshangout | 12/19/2022 11:20:32 PM |
znewcar1: IPHA 40% v66,3M c8.10 f79,1M Morning bear trap rip to 11.95 S@7.7 | znewcar1 | investorshangout | 09/18/2021 2:26:15 AM |
Is this going to be a monster presentation?! | Marvy | investorshub | 09/17/2021 1:43:21 PM |
News, Short Squeeze, Breakout and More Instantly...
Innate Pharma S.A. Company Name:
IPHA Stock Symbol:
NYSE Market:
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below. Participants will include Hervé...
Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate’s second generation ANKET ® , for the treatment of relapsed/refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma ...